Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H, Yan Z, Wang Y, Qi Y, Hu Y, Li P, Cao J, Zhang M, Xiao X, Shi M, Xia J, Ma S, Qiao J, Li H, Pan B, Qi K, Cheng H, Sun H, Zhu F, Sang W, Li D, Li Z, Zheng J, Zhao M, Liang A, Huang H, Xu K.
Zhang H, et al. Among authors: xia j.
Front Immunol. 2022 Aug 19;13:965224. doi: 10.3389/fimmu.2022.965224. eCollection 2022.
Front Immunol. 2022.
PMID: 36059496
Free PMC article.